CVRx Inc
$ 5.38
-8.50%
05 Jun - close price
- Market Cap 142,763,000 USD
- Current Price $ 5.38
- High / Low $ 5.95 / 5.33
- Stock P/E N/A
- Book Value 1.10
- EPS -2.01
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -1.07 %
- 52 Week High 11.30
- 52 Week Low 4.37
About
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Analyst Target Price
$11.17
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-12 | 2025-11-05 | 2025-08-04 | 2025-05-08 | 2025-02-04 | 2024-10-29 | 2024-07-29 | 2024-04-30 | 2024-01-25 | 2023-10-26 | 2023-07-25 |
| Reported EPS | -0.5 | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 |
| Estimated EPS | -0.5 | -0.44 | -0.5 | -0.52 | -0.57 | -0.38 | -0.47 | -0.55 | -0.54 | -0.55 | -0.58 | -0.58 |
| Surprise | 0 | -0.02 | 0.01 | -0.05 | 0.04 | -0.05 | -0.1 | -0.1 | -0.5 | 0.11 | 0.15 | 0.02 |
| Surprise Percentage | 0% | -4.5455% | 2% | -9.6154% | 7.0175% | -13.1579% | -21.2766% | -18.1818% | -92.5926% | 20% | 25.8621% | 3.4483% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVRX
2026-06-03 23:39:33
William Blair has reiterated its Buy rating for CVRx Inc (CVRX.US). Further details on the reasons for maintaining this rating or any specific financial analysis are not provided in this brief update.
2026-06-03 22:09:58
CVRx, Inc. director Joseph P. Slattery reported receiving compensation-related equity grants, including 8,720 shares of Common Stock and a stock option for 11,182 shares. The stock option has an exercise price of $5.43 and vests on the earlier of June 1, 2027, or the company’s 2027 annual meeting. After these grants, Slattery directly holds 39,365 Common shares, with these transactions classified as awards rather than open-market trades.
2026-06-03 22:09:58
CVRx, Inc. director Michael D. Dale filed a Form 3, an initial statement of beneficial ownership, with the SEC. The filing indicates Dale's position as a director but reports no current transactions or beneficial ownership of CVRx stock. This Form 3 provides transparency regarding new affiliations between company insiders and the firm.
2026-06-03 22:09:58
CVRx, Inc. director Martha Shadan received 8,720 shares of Common Stock as a no-cost grant and options for 11,182 shares with an exercise price of $5.43, expiring in 2036. These awards are compensation-related and increase her direct holdings in the company, with the options vesting on the earlier of June 1, 2027, or the company's 2027 annual meeting. The transaction is identified as a grant/award and not an open-market purchase or sale.
2026-06-03 13:24:00
Cvrx Inc. (NASDAQ: CVRX) is showing weak near and mid-term sentiment, though its long-term outlook is neutral. The stock is currently testing support, and if it holds, resistance is expected next. Institutional trading strategies, including position trading, momentum breakout, and risk hedging, have been generated by AI models with a notable 99.5:1 risk-reward setup targeting a 36.6% gain.
2026-06-02 20:39:40
CVRX's Barostim device targets a large, underserved heart failure market, showing significant improvements in quality of life and strong clinical evidence. The company is poised for growth due to regulatory advancements and expanded reimbursement, including new Medicare Advantage coverage, with projected 2026 revenues of $63M–$67M.
